570 results on '"Sevelda P"'
Search Results
2. Conventional versus reverse sequence of neoadjuvant epirubicin/cyclophosphamide and docetaxel: sequencing results from ABCSG-34
3. Inferior performance of established and novel serum inflammatory markers in diagnosing periprosthetic joint infections
4. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes
5. Multiplex PCR Unyvero i60 ITI application improves detection of low-virulent microorganisms in periprosthetic joint infections
6. IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes: JAKinibs suppress the interferon response in RA-FLSs
7. FOXO3 is involved in the tumor necrosis factor-driven inflammatory response in fibroblast-like synoviocytes
8. Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition: Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology
9. A Platform for the Synthesis of Oxidation Products of Bilirubin.
10. The influence of antibiotic-loaded cement spacers on the risk of reinfection after septic two-stage hip revision surgery
11. Schwangerschaftsbedingte Trophoblasttumoren
12. Korpuskarzinom
13. Zervixkarzinom
14. Total Femur Replacement After Tumor Resection: Limb Salvage Usually Achieved But Complications and Failures are Common
15. Onkologie und Molekularbiologie im Dialog
16. Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy—findings from clinical practice
17. Der Stellenwert der Second-Look-Operation beim Ovarialkarzinom
18. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
19. Body image and self-esteem in lower-limb amputees.
20. Impact of conization type on the resected cone volume: results of a retrospective multi-center study
21. Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer
22. Hormontherapie versus Chemo-Hormontherapie bei Patientinnen mit hormonrezeptorpositivem Mammakarzinom im Stadium I und II
23. Extracorporeal shockwave therapy in calcifying tendinitis of the shoulder
24. Validation of the S Classification of Sentinel Lymph Node and Microanatomic Location of Sentinel Lymph Node Metastases to Predict Additional Lymph Node Involvement and Overall Survival in Breast Cancer Patients
25. Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting
26. The Austrian fulvestrant registry: results from a prospective observation of fulvestrant in postmenopausal patients with metastatic breast cancer
27. Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
28. Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial
29. Zoledronate in a patient with pamidronate refractory hypercalcemia syndrome
30. Incidence of Anaemia in Breast Cancer Patients Receiving Adjuvant Chemotherapy
31. Lunar phases and survival of breast cancer patients – a statistical analysis of 3,757 cases
32. Prognostic influence of delays between exploratory and definitive laparotomy in the treatment of malignant ovarian tumors
33. 812MO Maintenance olaparib + bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 objective response rate (ORR) in the phase III PAOLA-1 trial
34. Gründung einer Spezialambulanz für Familienplanung bei entzündlich-rheumatischen Erkrankungen im KH Hietzing
35. Lupus, das Chamäleon
36. Color-coded and spectral Doppler flow in breast carcinomas – Relationship with the tumor microvasculature
37. Abgeschlossene und derzeit laufende adjuvante Therapieprotokolle bei Patientinnen mit operablem Mammakarzinom (II)
38. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial
39. Freie mitteilungen
40. Onkologie und Molekularbiologie im Dialog
41. Serum prostaglandin F2 alpha (PGFM) and oxytocin levels correlate with sonographic changes in the cervix in patients with preterm labor
42. A CA125 score as a prognostic index in patients with ovarian cancer
43. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients: 10-year results of a prospective randomised phase III study comparing carboplatin–cisplatin with cyclophosphamide–cisplatin
44. Second-line-Therapie des Ovarialkarzinoms
45. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev
46. The role of chemotherapy including ifosfamide for ovarian carcinoma
47. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
48. Prognostic value of monitoring tumour markers CA 15-3 and CEA during fulvestrant treatment
49. Stereocontrolled Synthesis of Pseurotin A2
50. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.